Abbott Laboratories stock falls 2.32 percent below yearly high effects? no
📉 Abbott Laboratories stock fell 2.32% to close at USD 101.09 on September 24, 2026.
💰 Q2 EPS of USD 1.31 exceeded the consensus estimate of USD 1.28 by USD 0.03.
📈 Revenue reached USD 12.59 billion, a 13% increase from the year-earlier quarter.
🎯 Full-year 2026 EPS guidance ranges from USD 5.45 to USD 5.60.
👥 Analyst consensus target price is USD 120.26 with 22 buy ratings out of 27 analysts.
📊 Market capitalization stands at approximately USD 174.9 billion as of late September.
📉 Stock trades USD 34.36 below its 52-week high of USD 135.45.
🔮 Third-quarter guidance projects EPS between USD 1.38 and USD 1.46.
Bullish Signals
- Abbott Laboratories reported Q2 EPS of USD 1.31, beating the consensus estimate of USD 1.28 by USD 0.03.
- Revenue grew to USD 12.59 billion in the second quarter, representing a 13% increase from the year-earlier quarter.
- The company provided full-year 2026 EPS guidance of USD 5.45 to USD 5.60, establishing a measurable earnings floor.
- Third-quarter earnings guidance ranges from USD 1.38 to USD 1.46, indicating continued growth expectations.
- Analyst consensus target price of USD 120.26 suggests significant upside potential from current trading levels.
Risk Factors
- Stock price declined 2.32% on September 24, 2026, closing at USD 101.09 below the previous close.
- Current share price of USD 101.09 trades significantly below the 52-week high of USD 135.45.
Full Analysis
Abbott Laboratories stock declined 2.32% to close at USD 101.09 on September 24, 2026, trading below its yearly high despite recent positive earnings data. The company's market capitalization stood at approximately USD 174.9 billion with a daily trading volume of over 6 million shares.
Second-quarter financial results released earlier in July showed strong performance with EPS of USD 1.31, beating the consensus estimate of USD 1.28. Revenue reached USD 12.59 billion, representing a 13% increase from the year-earlier quarter and exceeding analyst expectations.
Management provided forward guidance for full-year 2026 EPS between USD 5.45 and USD 5.60, along with third-quarter earnings projections ranging from USD 1.38 to USD 1.46. Analyst sentiment remains bullish with an average 12-month target price of USD 120.26 supported by 22 buy ratings among 27 analysts.
The stock currently trades significantly below its 52-week high of USD 135.45, creating a potential upside opportunity relative to the consensus analyst target. The wide dispersion in individual analyst targets suggests varying expectations for future growth trajectories.
